Clinical trials: Docetaxel, completed
Nasopharyngeal Neoplasms, Carcinoma
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
The primary objective is to estimate the Complete Response rate of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) compared to cisplatin-5-fluorouracil (CF) in the Induction treatment of Nasopharyngeal Carcinoma…
- Trial name
- NCT00565448
- Testing
- docetaxel, cisplatin, 5-fluorouracil
- Where
- 26 sites in Algeria, Brazil and 12 more
- Volunteers
- 75 people
- Sponsor
- Sanofi
Advanced Non-Squamous Non-Small Cell Lung Cancer
Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation
To compare the differential influence of 1st line doublet chemotherapy containing Docetaxel versus Pemetrexed on clinical efficacy of Erlotinib as a second line therapy in patients with relapsed or progressed non-squamous NSCLC.
- Trial name
- NCT01204307
- Testing
- Docetaxel/cisplatin, Pemetrexed/cisplatin
- Where
- 4 sites in Taiwan
- Volunteers
- 101 people
- Sponsor
- Chang Gung Memorial Hospital
Advanced Cancer
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
To determine safety and maximum tolerated dose of brivanib alaninate when administered in combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel chemotherapy to subjects with advanced or metastatic…
- Trial name
- NCT00798252
- Testing
- Capecitabine, Doxorubicin, Ixabepilone
- Where
- 5 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Bristol-Myers Squibb
Stage IV Gastric Cancer With Metastasis
Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer
A maximum of 8 cycles of chemotherapy will be administered. Depending on patients' tolerability, 8 cycles of chemotherapy will be given to the patients.
- Trial name
- XPID (NCT01525771)
- Testing
- Docetaxel
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Asan Medical Center
Non-small Cell Lung Cancer, Breast Cancer
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer.
- Conditions
- Non-small Cell Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT00327288
- Testing
- imexon, docetaxel
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- AmpliMed Corporation
Sarcoma
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
1.1 To determine the recommended phase II dose for gemcitabine in combination with a fixed dose of docetaxel and bevacizumab. 1.2 To determine the efficacy of the combination of gemcitabine, docetaxel, and bevacizumab in patients…
- Trial name
- NCT00276055
- Testing
- Gemcitabine, Docetaxel and Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- New Mexico Cancer Research Alliance
Head and Neck Cancer
Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck
The proposed study is a first-in-human pilot of a novel anti-cancer strategy: Metnase inhibition to potentiate DNA damaging chemotherapy.
- Trial name
- NCT01275183
- Testing
- raltegravir and cisplatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- New Mexico Cancer Research Alliance
Head and Neck Cancer
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00281840
- Testing
- bevacizumab, docetaxel, conventional surgery
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer(NSCLC) is the leading cause of death in Korean men after stomach cancer. Surgical resection plays a main role for curative treatment.
- Trial name
- NCT00326378
- Testing
- consolidation chemotherapy with Docetaxel plus cisplatin, CCRT arm without consolidation chemotherapy
- Where
- South Korea
- Volunteers
- 434 people
- Sponsor
- Samsung Medical Center
Non-Small Cell Lung Cancer
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin, docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with completely resected stage IB, II, and select III…
- Trial name
- NCT00621049
- Testing
- Docetaxel/Carboplatin/Bevacizumab/Erlotinib, Docetaxel/Carboplatin
- Where
- 26 sites in United States
- Volunteers
- 112 people
- Sponsor
- SCRI Development Innovations, LLC
Squamous Cell Carcinoma of the Hypopharynx, Larynx Carcinoma
Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)
The DeLOS II trial is a multicenter randomised phase II trial investigating a TP/5-Fluorouracil (TPF)-chemotherapy with or without cetuximab for Patients with only by laryngectomy operable carcinoma of the larynx/hypopharynx.
- Trial name
- DeLOS II (NCT00508664)
- Testing
- Radiation, Cetuximab, Docetaxel
- Where
- 27 sites in Austria, Germany
- Volunteers
- 180 people
- Sponsor
- ClinAssess
Cholangiocarcinoma Cancer, Gallbladder Cancer
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
To assess the feasibility of administering induction chemotherapy with gemcitabine and docetaxel followed by concurrent radiation and continuous infusion 5FU and consolidation gemcitabine/docetaxel chemotherapy.
- Conditions
- Cholangiocarcinoma Cancer, Gallbladder Cancer, Pancreatic Cancer, Ampullary Cancer
- Trial name
- NCT00660699
- Testing
- Gemcitabine, Docetaxel, Radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
The combination of taxanes, and especially docetaxel, with an anthracycline seems to be an important part of the chemotherapy regimens used in the adjuvant setting of patients with early-stage node-positive breast cancer…
- Trial name
- NCT00424606
- Testing
- Docetaxel, Epirubicin
- Where
- 12 sites in Greece
- Volunteers
- 658 people
- Sponsor
- Hellenic Oncology Research Group
Gastric Cancer
Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric Cancer
This study will determine the feasibility of adjuvant chemotherapy and chemo-radiotherapy for patients with surgically resected adenocarcinoma of the stomach and gastro-esophageal junction.
- Trial name
- NCT00718913
- Testing
- Docetaxel, Cisplatin, Capecitabine
- Where
- 8 sites in Greece
- Volunteers
- 40 people
- Sponsor
- Hellenic Oncology Research Group
Upper GI Cancer, Cisplatin Adverse Reaction
Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma
Cisplatin is a potent chemotherapeutic agent that has been widely used to treat many solid tumours. acute renal failure, despite conservative fluid and electrolyte management, frequently reported adverse event and limiting…
- Trial name
- NCT01829178
- Testing
- Silymarin, chemotherapy
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Tehran University of Medical Sciences
Adult Solid Neoplasm, Inflammatory Breast Carcinoma
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
Phase I/II trial to study the effectiveness of neoadjuvant tipifarnib combined with docetaxel and capecitabine in treating patients who have locally advanced or metastatic solid tumors or stage IIIA or stage IIIB breast cancer.
- Conditions
- Adult Solid Neoplasm, Inflammatory Breast Carcinoma, Male Breast Carcinoma, Stage IIIA Breast Cancer
- Trial name
- NCT00070252
- Testing
- Capecitabine, Docetaxel, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
Primary Objective: 1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1.
- Trial name
- NCT00500110
- Testing
- Docetaxel, Imatinib Mesylate, Leuprolide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
RATIONALE: Calcitriol may cause pancreatic cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00238199
- Testing
- calcitriol, docetaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- OHSU Knight Cancer Institute
Head and Neck Cancer
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
This is a study for patients who have head and neck cancer that has recurred in the body area where they previously received radiation, and for whom surgery is not planned.
- Trial name
- NCT00713219
- Testing
- IMRT, cetuximab, docetaxel
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer
The purpose of this study is to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.
- Trial name
- NCT00209092
- Testing
- Docetaxel, Capecitabine
- Where
- 19 sites in United States
- Volunteers
- 51 people
- Sponsor
- Emory University